Background/Aim: The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Patients and Methods: Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. Results: In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Conclusion: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.
|Number of pages||6|
|Publication status||Published - Aug 1 2018|
ASJC Scopus subject areas
- Cancer Research